Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | ELANE | P08246 | 2/20 | 0.58 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 5/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.54 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12493735 | 0.88 | CTSK (0.56) | ATMELANECTSKSYKCTRB1 | |
| SCHEMBL12493740 | 0.88 | CTSK (0.56) | ATMELANECTSKSYKCTRB1 | |
| SCHEMBL12442117 | 0.86 | CTRB1 (0.57) | ATMELANECTSKSYKCTRB1 | |
| SCHEMBL25465074 | 0.86 | CTRB1 (0.57) | ATMELANECTSKSYKCTRB1 | |
| SCHEMBL13201865 | 0.86 | SYK (0.56) | ATMELANECTSKSYKCTRB1 | |
| SCHEMBL12493219 | 0.85 | SYK (0.54) | ATMELANECTSKSYKCTRB1 | |
| SCHEMBL12493217 | 0.85 | SYK (0.54) | ATMELANECTSKSYKCTRB1 | |
| SCHEMBL12682126 | 0.85 | ATM (0.53) | ATMELANECTSKSYKCTRB1 | |
| SCHEMBL12682187 | 0.84 | CTSS (0.59) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL14704026 | 0.84 | ATM (0.61) | ATMELANECTSKCTRB1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871904-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140107318-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637457-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130172276-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | ATM 4055/4885ELANE 80/4885CTSK 76/4885 |
| US-20130172276-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | ATM 3148/4885ELANE 123/4885CTSK 91/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | ATM 4055/4885ELANE 80/4885CTSK 76/4885 |
| US-20140107318-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | ATM 3148/4885ELANE 123/4885CTSK 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.